Inhibition of Type 4 Cyclic Nucleotide Phosphodiesterase Blocks Intracellular TLR Signaling in Chronic Lymphocytic Leukemia and Normal Hematopoietic Cells

Ying Tan, Amanda A. Watkins, Benjamin B. Freeman, John A. Meyers, Ian R. Rifkin and Adam Lerner

*J Immunol* 2015; 194:101-112; Prepublished online 21 November 2014; doi: 10.4049/jimmunol.1401854
http://www.jimmunol.org/content/194/1/101

References This article cites 72 articles, 28 of which you can access for free at: http://www.jimmunol.org/content/194/1/101.full#ref-list-1

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

Subscription Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

*The Journal of Immunology* is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
Inhibition of Type 4 Cyclic Nucleotide Phosphodiesterase Blocks Intracellular TLR Signaling in Chronic Lymphocytic Leukemia and Normal Hematopoietic Cells

Ying Tan,* Amanda A. Watkins,† Benjamin B. Freeman,* John A. Meyers,* Ian R. Rifkin,† and Adam Lerner*,‡

A subset of chronic lymphocytic leukemia (CLL) BCRs interacts with Ags expressed on apoptotic cells, suggesting that CLL BCRs have the potential to internalize apoptotic cell RNA- or DNA-containing fragments with resultant activation of TLR7 or TLR9, respectively. By blocking cAMP degradation, type 4 cAMP phosphodiesterase (PDE4) inhibitors activate cAMP-mediated signaling and induce apoptosis in CLL cells. In this study, we show that autologous irradiated leukemic cells induce proliferation in CLL cells and that such proliferation is blocked by a TLR7/8/9 inhibitor, by DNase, and by the PDE4 inhibitor rolipram. Rolipram also inhibited CLL cell proliferation induced by synthetic TLR7 and TLR9 agonists, as well as TLR agonist-induced costimulatory molecule expression and TNF-α (but not IL-6 or IL-10) production. Whereas treatment with a TLR9 agonist protected IgH V region unmutated, but not mutated, CLL cells from apoptosis, PDE4 inhibitors augmented apoptosis in both subtypes, suggesting that cAMP-mediated signaling may abrogate a TLR9-mediated survival signal in prognostically unfavorable IgH unmutated CLL cells. Rolipram inhibited both TLR7/8- and TLR9-induced IFN regulatory factor 5 and NF-κB p65 nuclear translocation. PDE4 inhibitors also blocked TLR signaling in normal human immune cells. In PBMC and CD14-positive monocytes, PDE4 inhibitors blocked IFN-α or TNF-α (but not IL-6) production, respectively, following stimulation with synthetic TLR agonists or RNA-containing immune complexes. These results suggest that PDE4 inhibitors may be of clinical utility in CLL or autoimmune diseases that are driven by TLR-mediated signaling. The Journal of Immunology, 2015, 194: 101–112.

One current hypothesis as to the origin of chronic lymphocytic leukemia (CLL) cells is that they are derived from marginal zone B cells whose normal function includes clearance of apoptotic debris (1). Consistent with such a hypothesis, at least a subset of CLL cells has been shown to express BCRs that react with Ags expressed on apoptotic cells (2–5). Patients with CLL whose clonal unmutated IgH V region (IGHV) sequence closely resembles germline sequence (>98% homology) have a significantly poorer prognosis than those with mutated IgH regions (6, 7). Among CLL patients whose clonal BCRs bind to apoptotic cells, there is significant enrichment for BCRs that have unmutated IgH sequences (3).

The concept that some CLL clones may derive a positive proliferation signal from apoptotic cells in their environment focuses attention on the potential pathophysiologic importance of TLRs in CLL. TLRs play a key role in the response of immune cells to patterned Ags present in microorganisms, including ssRNA (TLR7 and TLR8) and CpG-enriched DNA (TLR9) (8). CLL cells express TLR1, 2, 6, 7, and 9, but not TLR8 (9–13). Treatment of CLL cells and TLR1, 2, 6, 7, and 9, but not TLR8 (9–13). Treatment of CLL cells with synthetic TLR ligands induces CLL proliferation (10). Although TLR7 and TLR9 agonists have been shown to upregulate immunostimulatory molecules on CLL cells, thereby potentially rendering them more sensitive to a host immune response, trials examining TLR agonist therapy have to date not demonstrated significant clinical responses (14, 15).

As TLR7, TLR8, and TLR9 normally respond to exogenous ligands in pathogens that have been internalized and require transfer of TLRs from the endoplasmic reticulum to an endolysosomal compartment, the relevance of TLR signaling to the pathophysiology of CLL is initially not apparent (16, 17). However, studies of autoimmunity have demonstrated that autoantibodies to BCRs that bind endogenous RNA or DNA or immune complexes (ICs) can internalize autoantigens derived from apoptotic cells and activate B cell TLR7 and TLR9 signaling (18–20). Similarly, dendritic cells can internalize RNA- or DNA-containing IC via FcRs resulting in TLR7- or TLR9-dependent dendritic cell activation (21, 22). Thus, it is plausible that CLL BCRs reactive with apoptotic Ags could serve to deliver endogenous RNA or DNA to endolysosomal TLR7 and TLR9. Of note, activating mutations in the TLR adapter protein MyD88 have been identified in 2–10% of CLL patients, and B cell activation induced by this MyD88 mutation requires TLR9 (23–26).

G protein–coupled receptors are powerful modulators of signal transduction in the immune system, in part through Gs-mediated activation of adenylate cyclase and subsequent protein kinase A–mediated phosphorylation of a wide variety of critical immune cell signal transduction enzymes (27). One pharmacologic approach to
mimicking the generally immunosuppressive effects of cAMP signaling in the immune system is the use of cyclic nucleotide phosphodiesterase inhibitors, drugs that block the catabolism of cAMP, thereby prolonging signaling by this second messenger. Even in the absence of specific stimulation of G protein–coupled receptors, cAMP signaling through the effectors protein kinase A (PKA) and exchange protein activated by cAMP, as judged by Rap1 activation, the prototypic PDE4 inhibitor rolipram also induces apoptosis in CLL cells and augments glucocorticoid-mediated apoptosis (29–31).

PDE4B plays a critical role in the regulation of murine macrophage responses to LPS, a bacterial product that activates the plasma membrane-bound TLR4, as peripheral blood leukocytes and macrophages from mice lacking a functional PDE4B gene fail to produce TNF-α in response to LPS stimulation (32, 33). However, the precise mechanism by which PDE4B-modulated cAMP signaling regulates LPS-induced signaling remains undetermined, and the generalizability of this observation to intracellular TLRs such as TLR7 and TLR9 is undetermined. Given the growing evidence for a potential pathophysiologic role for intracellular TLRs in CLL and in autoimmune diseases, we sought to determine whether PDE4 inhibitors could inhibit TLR7- and TLR9-mediated signaling in CLL and normal circulating hematopoietic cells.

Materials and Methods

Materials
Type A CpG oligodeoxynucleotide (2216), type B CpG oligodeoxynucleotide (2006), R848, and PamCSK4 were purchased from InvivoGen. Rolipram (Enzo Life Science) and roflumilast (Santa Cruz Biotechnology) were dissolved with DMSO. The final DMSO concentration in the experiments described in this study did not exceed 0.1%. A oligonucleotide-based TLR7/8/9 antagonist was a gift of Idera Pharmaceuticals and was dissolved in sterile, endotoxin-free water (34). DNase I was obtained from Roche.

Cell isolation
Blood samples from flow cytometry–verified CLL patients who were untreated or at least 6 mo postchemotherapy were drawn after Institutional Review Board–approved informed consent. CLL cells or PBMCs from healthy donors were isolated and cultured, as previously described (35). Monocytes were isolated with human CD14 MicroBeads (Miltenyi Biotec).

Proliferation assays
One million CLL cells/well were incubated in 96-well dishes at 37˚C for 3 d. Phenotypic analyses of the live cell population used for the proliferation assays typically showed >95% CD5−CD19− lymphocytes, 3–4% T cells, and no more than 1.5% CD14+ monocytes. Eighteen hours before harvesting, the cells were pulsed with 1 µCi/well 3H-thymidine. For studies involving irradiated cells, 24 h after isolation, CLL cells were removed from culture dishes and irradiated using a cesium 131 irradiator (50 Gy). After an additional 24 h of cell culture, 0.5–2.0 million irradiated cells were added to one million untreated leukemic cells/well and incubated for 6 d. Proliferation was obtained from Roche.

Flow cytometry
After staining with fluorescent Abs against CD19, CD40, CD54, and appropriate isotype controls (BD Pharmingen), CLL cell samples were acquired using a LSRII flow cytometer (BD Biosciences). Data were analyzed with FlowJo software (10.0.6; Tree Star).

Statistical analysis
Unless otherwise indicated, statistical analysis of each set of conditions for a specific TLR agonist was performed by two-way ANOVA with multiple comparison and Tukey’s post hoc test for significance using Prism 6.0 software.

Results

PDE4 inhibitors block CLL cell proliferation induced by autologous irradiated apoptotic cells

Given prior studies suggesting that CLL BCRs frequently bind to Abs expressed on apoptotic cells, we sought to determine whether apoptotic autologous leukemic cells could induce CLL cell proliferation. Freshly isolated CLL cells were cultured overnight, then transferred to new culture plates, and combined with increasing numbers of autologous CLL cells that had been irradiated (50 Gy) the previous day. Proliferation was assessed 6 d later by titrated thymidine assay. When measured at 24 h, in nine CLL samples so tested, apoptosis was 11.8 ± 11.6% (SD) in control cells and 49.6 ± 21.8% in irradiated cells (p = 0.0004). When measured after 5 d of culture, 95 ± 8% of the irradiated cells had undergone apoptosis. When cultured alone, irradiated cells demonstrated very little titrated thymidine uptake, even at the highest cell dosage studied (Fig. 1A [open circles]). In eight CLL patients examined, addition of irradiated cells at either a 1:1 or 2:1 irradiated/unirradiated cell ratio led to augmented levels of proliferation of the CLL cell culture (Fig. 1A [closed circles]). When we examined leukemic cells from a CLL patient with known deletion of 17p and therefore a lack of apoptotic response to irradiation (data not shown), no increase in proliferation following the
FIGURE 1. Autologous irradiated cells induce proliferation of CLL cells, and this is inhibited by treatment with either DNase or the PDE4 inhibitor rolipram. (A) One million leukemic cells/well were cultured for 6 d in media alone with increasing concentrations of autologous leukemic cells that had been previously irradiated (solid line, filled circles). As a control, increasing concentrations of the irradiated autologous leukemic cells were also cultured for the same time period in the absence of the one million unirradiated cells (dotted line, open circles). One patient’s leukemic cells (lower right, patient 7) were known to carry a 17p deletion conferring resistance to radiation-induced apoptosis. Parallel cultures were carried out in the presence of the PDE4 inhibitor rolipram at 20 μM (dashed line, upright triangles; n = 7) or following overnight treatment of the irradiated cells with 20 U/ml DNase (dash/dotted line, inverted triangles; n = 6). Proliferation was measured by triitated thymidine incorporation after 6 d. (B) Nine IGHV unmutated and four IGHV mutated leukemic samples were cultured with increasing concentrations of irradiated autologous leukemic cells. Data from IGHV unmutated samples are shown with solid lines, whereas IGHV mutated samples are shown with dotted lines. (C) Combined proliferation data from the eight CLL patients without a 17p deletion shown in (A). Fold proliferation was calculated for each condition relative to proliferation for that individual’s CLL cells in the absence of added irradiated cells. *p < 0.05, **p < 0.01. (D) Effect of a TLR7/8/9 antagonist on CLL proliferation induced by irradiated autologous CLL cells. Solid lines with filled circles represent proliferation of CLL cells cultured alone or with increasing numbers of autologous irradiated leukemic cells. The dotted line with open circles represents the irradiated cells cultured alone. The dashed line with filled squares represents proliferation of CLL cells treated with the TLR7/8/9 antagonist (3 μg/ml) prior to culture alone or with autologous irradiated leukemic cells.
addition of irradiated autologous cells was observed, consistent with the hypothesis that apoptotic cells are required to induce proliferation of the unirradiated cells (Fig. 1A, patient 7).

As prior studies have suggested that, among CLL patients whose clonal BCRs bind to apoptotic cells, there is significant enrichment for BCRs that have unmutated IGHV sequences, we sequenced the IG VH genes of the CLL patients (Table I) (3). Among the total of 13 CLL samples examined for proliferative responses to autologous irradiated cells (9 unmutated IGHV and 4 mutated IGHV), there was a trend in which the strongest proliferative response to such a stimulus occurred in IGHV unmaturated CLL cells. As shown in Fig. 1B, 7 of the top 8 responding CLL samples were IGHV unmaturated.

To determine whether DNA derived from apoptotic cells might play a role in the induction of proliferation by irradiated autologous leukemic cells, irradiated cells were treated with DNase overnight prior to coculture. DNase treatment reduced the proliferative response observed following coculture of live and irradiated cells (Fig. 1A, 1C). An oligonucleotide-based inhibitor of TLR7, TLR8, and TLR9 signaling (3 μg/ml) also reduced CLL cell proliferation induced by autologous irradiated cells in four CLL patient samples so tested, but had little or no effect on basal proliferation (Fig. 1D) (34).

Prior studies have demonstrated that PDE4-regulated cAMP-mediated signaling inhibits a variety of lymphoid signal transduction pathways (40). To assess the ability of PDE4 inhibitors to alter CLL proliferation in response to autologous apoptotic cells, the prototypic PDE4 inhibitor rolipram (20 μM) was added at the initiation of the coculture experiments. Rolipram treatment markedly reduced proliferation in the five coculture samples examined (Fig. 1A, 1C).

**PDE4 inhibitors reduce TLR agonist-induced expression of CD40 and CD54 in CLL cells**

Although the studies described above demonstrate that exposure to autologous apoptotic cells can drive CLL cell proliferation, at least in part through TLR-mediated pathways, and that such proliferation can be abrogated by PDE4 inhibitors, such an experimental approach does not easily address the contribution and specificity of BCR and TLR signaling in the response to this complex stimulus. We therefore next more directly examined the response of CLL cells to synthetic TLR ligands. TLR ligands augment the expression on CLL cells of costimulatory molecules, including CD40 and CD54 (9–12). We assessed expression of CD40 and CD54 on CD19+ leukemic cells 72 h after treatment with varying doses of synthetic agonists. The intracellular TLR7 was activated with the imidazoquinoline R848 (resiquimod) and the intracellular TLR9 with the oligonucleotide CpG-B (2006) (41, 42). As a control, we also treated the cells with the triacylated bacterial lipopeptide Pam3-Cys-Ser-Lys4 (Pam3CSK4), a synthetic ligand for the heterodimeric cell surface TLR1/2 (43). Each of the three TLR agonists substantially augmented expression of both CD40 and CD54 in CLL cells. Cotreatment with rolipram inhibited the induction of CD40 and CD54 expression for each of the three TLR agonists tested with the exception of Pam3CSK4-stimulated CD40 expression, in which there was a nonsignificant trend toward inhibition (Fig. 2).

**Inhibition of PDE4 reduces TLR agonist-induced proliferation in CLL cells**

TLR ligands induce the proliferation of both normal and malignant B cells (10). To assess the effect of PDE4 inhibition on TLR ligand-induced CLL cell growth, leukemic cells from 21 CLL patients were stimulated with graded doses of the three synthetic TLR1/2, TLR7, and TLR9 agonists in the presence or absence of rolipram (20 μM). The TLR-1/2, TLR7, and TLR9 agonists all induced CLL proliferation 72 h after stimulation. Cotreatment with rolipram reduced such proliferation 2- to 3-fold for all conditions tested (Fig. 3A).

To assess the effect of IGHV mutational status on the sensitivity of CLL cells to TLR ligands and to PDE4 inhibitors, we sequenced

**Table I. Clinical and molecular characteristics of CLL patients examined in this study**

<table>
<thead>
<tr>
<th>No.</th>
<th>Age</th>
<th>Sex</th>
<th>Rai Stage</th>
<th>WBC</th>
<th>Treatment</th>
<th>IGHV Mutation</th>
<th>IGHV</th>
<th>IGHI</th>
<th>IGHD</th>
<th>CLL FISH Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>78</td>
<td>F</td>
<td>IV</td>
<td>70000</td>
<td>Chlorambucil, alemtuzumab, CHOP, FCR</td>
<td>Unmutated</td>
<td>1-69</td>
<td>2</td>
<td>2</td>
<td>Del 17p</td>
</tr>
<tr>
<td>2</td>
<td>83</td>
<td>F</td>
<td>0</td>
<td>30,000</td>
<td>CHOP</td>
<td>Mutated</td>
<td>3-30</td>
<td>3</td>
<td>3</td>
<td>Normal</td>
</tr>
<tr>
<td>3</td>
<td>73</td>
<td>M</td>
<td>0</td>
<td>85,000</td>
<td>None</td>
<td>Mutated</td>
<td>1-3</td>
<td>4</td>
<td>3</td>
<td>Del 13q</td>
</tr>
<tr>
<td>4</td>
<td>62</td>
<td>M</td>
<td>I</td>
<td>59,000</td>
<td>None</td>
<td>Mutated</td>
<td>4-4</td>
<td>4</td>
<td>1</td>
<td>Normal</td>
</tr>
<tr>
<td>5</td>
<td>75</td>
<td>M</td>
<td>0</td>
<td>111,000</td>
<td>FCR</td>
<td>Unmutated</td>
<td>1-69</td>
<td>4</td>
<td>3</td>
<td>Normal</td>
</tr>
<tr>
<td>6</td>
<td>69</td>
<td>F</td>
<td>III</td>
<td>94,000</td>
<td>None</td>
<td>Mutated</td>
<td>1-46</td>
<td>n/a</td>
<td>n/a</td>
<td>Normal</td>
</tr>
<tr>
<td>7</td>
<td>64</td>
<td>F</td>
<td>II</td>
<td>76,000</td>
<td>FCR, R-bendamustine, lenalidomide</td>
<td>Unmutated</td>
<td>6-01</td>
<td>n/a</td>
<td>n/a</td>
<td>Del 17p</td>
</tr>
<tr>
<td>8</td>
<td>69</td>
<td>F</td>
<td>0</td>
<td>34,000</td>
<td>None</td>
<td>Unmutated</td>
<td>4-34</td>
<td>4</td>
<td>6</td>
<td>Del 13q</td>
</tr>
<tr>
<td>9</td>
<td>55</td>
<td>M</td>
<td>I</td>
<td>18,000</td>
<td>None</td>
<td>Mutated</td>
<td>1-2</td>
<td>4</td>
<td>6</td>
<td>Del 13q</td>
</tr>
<tr>
<td>10</td>
<td>58</td>
<td>F</td>
<td>0</td>
<td>19,000</td>
<td>Chlorambucil, FR</td>
<td>Unmutated</td>
<td>1-69</td>
<td>n/a</td>
<td>n/a</td>
<td>Normal</td>
</tr>
<tr>
<td>11</td>
<td>83</td>
<td>F</td>
<td>0</td>
<td>79,000</td>
<td>FCR</td>
<td>Unmutated</td>
<td>4-4</td>
<td>4</td>
<td>2</td>
<td>Del 6q, Tri 12</td>
</tr>
<tr>
<td>12</td>
<td>61</td>
<td>M</td>
<td>0</td>
<td>16,000</td>
<td>None</td>
<td>Mutated</td>
<td>1-69</td>
<td>6</td>
<td>6</td>
<td>Tri 12</td>
</tr>
<tr>
<td>13</td>
<td>53</td>
<td>M</td>
<td>II</td>
<td>32,000</td>
<td>FCR</td>
<td>Unmutated</td>
<td>1-69</td>
<td>6</td>
<td>3</td>
<td>Del 11q</td>
</tr>
<tr>
<td>14</td>
<td>43</td>
<td>F</td>
<td>III</td>
<td>27,000</td>
<td>FR, lenalidomide</td>
<td>Unmutated</td>
<td>1-69</td>
<td>4</td>
<td>3</td>
<td>Del 13q</td>
</tr>
<tr>
<td>15</td>
<td>55</td>
<td>F</td>
<td>I</td>
<td>34,000</td>
<td>FCR</td>
<td>Unmutated</td>
<td>5-51</td>
<td>2</td>
<td>1</td>
<td>Normal</td>
</tr>
<tr>
<td>16</td>
<td>64</td>
<td>M</td>
<td>0</td>
<td>27,000</td>
<td>None</td>
<td>Unmutated</td>
<td>1-69</td>
<td>6</td>
<td>3</td>
<td>Tri 12</td>
</tr>
<tr>
<td>17</td>
<td>73</td>
<td>M</td>
<td>I</td>
<td>147,000</td>
<td>None</td>
<td>Unmutated</td>
<td>5-a</td>
<td>6</td>
<td>6</td>
<td>Normal</td>
</tr>
<tr>
<td>18</td>
<td>73</td>
<td>M</td>
<td>IV</td>
<td>19,000</td>
<td>Chlorambucil, FC, FCR</td>
<td>Unmutated</td>
<td>1-69</td>
<td>4</td>
<td>5</td>
<td>Normal</td>
</tr>
<tr>
<td>19</td>
<td>78</td>
<td>F</td>
<td>II</td>
<td>34,000</td>
<td>None</td>
<td>Unmutated</td>
<td>7-4</td>
<td>5</td>
<td>3</td>
<td>Normal</td>
</tr>
<tr>
<td>20</td>
<td>84</td>
<td>F</td>
<td>0</td>
<td>23,000</td>
<td>None</td>
<td>Mutated</td>
<td>1-69</td>
<td>6</td>
<td>2</td>
<td>N.D.</td>
</tr>
<tr>
<td>21</td>
<td>66</td>
<td>M</td>
<td>0</td>
<td>19,300</td>
<td>None</td>
<td>Mutated</td>
<td>3-23</td>
<td>5</td>
<td>4</td>
<td>Normal</td>
</tr>
<tr>
<td>22</td>
<td>64</td>
<td>M</td>
<td>0</td>
<td>19,000</td>
<td>None</td>
<td>Mutated</td>
<td>1-69</td>
<td>4</td>
<td>5</td>
<td>N.D.</td>
</tr>
<tr>
<td>23</td>
<td>79</td>
<td>M</td>
<td>I</td>
<td>39,600</td>
<td>None</td>
<td>Unmutated</td>
<td>1-69</td>
<td>6</td>
<td>3</td>
<td>N.D.</td>
</tr>
<tr>
<td>24</td>
<td>77</td>
<td>F</td>
<td>0</td>
<td>35,200</td>
<td>None</td>
<td>N.D.</td>
<td>N.D.</td>
<td>N.D.</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
</tbody>
</table>

C, cyclophosphamide; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; F, fludarabine; FISH, fluorescent in situ hybridization; n/a, not available; N.D., not done; R, rituximab.
the patients’ clonal IGHV regions (Table I). Statistically significant reductions in proliferation following rolipram treatment were observed for three and five of seven TLR ligand-stimulated conditions for the unmutated and mutated IGHV samples, respectively (Fig. 3B). Our results thus suggest that PDE4 inhibitors modulate TLR7 and TLR9 signaling in both IGVH mutated and unmutated CLL cells. We also sequenced leukemic cell genomic DNA for activating L265P MyD88 mutations. Such a mutation was not identified in the patients examined in this study.

To determine whether the effects observed with rolipram are specific to this compound or more generally true of PDE4 inhibitors, we performed experiments with roflumilast, a structurally distinct PDE4 inhibitor that is approved for clinical use (44). Rolipram and roflumilast inhibited TLR7 and TLR9 ligand-induced CLL cell proliferation to a similar degree (Fig. 3C).

TLR9 stimulation reduces basal apoptosis in IGHV unmutated but not mutated CLL

Both PDE4 inhibitors and TLR ligands have been reported to induce apoptosis in CLL cells (11, 36). To determine whether PDE4 inhibitor-induced CLL apoptosis might be altered by endogenous TLR signaling, leukemic cells from 20 CLL patients were treated with the same graded doses of TLR1/2, TLR7, and TLR9 ligands described above, with or without combined rolipram treatment, followed by assessment for apoptosis at 72 h using a Hoechst 33342 flow cytometric assay (36). Treatment with rolipram alone or rolipram in combination with a TLR agonist modestly augmented CLL apoptosis relative to DMSO vehicle alone (Fig. 4A). In contrast to some prior reports, none of the three TLR agonists tested induced apoptosis in CLL cells in the absence of rolipram, and addition of the TLR ligands to rolipram had no statistically significant effect relative to rolipram alone (Fig. 4A). CLL cells from nine patients were incubated with either rolipram (20 μM) or roflumilast (1 μM) in the presence or absence of TLR1/2, TLR7, or TLR9 agonists. At these doses, rolipram and roflumilast induced similar levels of apoptosis in CLL cells, and, again, addition of the TLR ligands to rolipram had no statistically significant effect on such apoptosis (Fig. 4B).

CLL cells with unmutated IGHV regions are more likely to have autoreactive BCRs that bind to Ags expressed on the surface of myosin H chain–expressing apoptotic cells, suggesting that IGHV region mutation status may influence CLL cell survival in the presence of TLR ligands (2–5). We found that the patterns of death or survival in response to treatment with TLR ligands and/or rolipram differed between these two groups of patients. Basal levels of apoptosis were not significantly affected by...
IGHV mutation status. Strikingly, however, IGHV region unmutated CLL cells had a statistically significant reduction in apoptosis following treatment with the TLR9 agonist CpG-B at all doses tested. No such reduction was observed in IGHV region mutated CLL samples (Fig. 4E). A comparable effect was not observed following treatment with TLR7/8 or TLR1/2 agonists (Fig. 4C, 4D). In some contrast to the effects of treatment with a TLR9 agonist, treatment with the PDE4 inhibitor rolipram (20 μM), followed by assessment for proliferation by tritiated thymidine assay. Each patient’s level of proliferation is expressed as fold induction relative to their own basal proliferation rate (stimulus CPM/vehicle-only CPM). The mean fold induction of proliferation is shown as a horizontal bar. (B) The proliferation data presented in (A) are shown with patient samples subcategorized by their IGHV mutational status. *p < 0.05, **p < 0.01. (C) Leukemic cells from nine CLL patients were treated with TLR1/2, TLR7, and TLR9 ligands in the presence or absence of two structurally distinct PDE4 inhibitors, rolipram (20 μM) and roflumilast (1 μM), followed by assessment for proliferation as per (A). *p < 0.05 compared with the same stimulus without PDE4 inhibitor.

FIGURE 3. PDE4 inhibitors inhibit CLL cell proliferation induced by TLR1/2, TLR7, and TLR9 ligands. (A) Leukemic cells from CLL patients (n = 21) were cultured for 72 h in media with vehicle alone (DMSO), the TLR1/2 ligand Pam3CSK4 (1 or 3 μg/ml), the TLR7 ligand R848 (0.3 or 3 μg/ml), or the TLR9 ligand CpG-B (0.3, 1, or 5 μg/ml) in the absence or presence of the PDE4 inhibitor rolipram (20 μM), followed by assessment for proliferation by tritiated thymidine assay. Each patient’s level of proliferation is expressed as fold induction relative to their own basal proliferation rate (stimulus CPM/vehicle-only CPM). The mean fold induction of proliferation is shown as a horizontal bar. (B) The proliferation data presented in (A) are shown with patient samples subcategorized by their IGHV mutational status. *p < 0.05, **p < 0.01. (C) Leukemic cells from nine CLL patients were treated with TLR1/2, TLR7, and TLR9 ligands in the presence or absence of two structurally distinct PDE4 inhibitors, rolipram (20 μM) and roflumilast (1 μM), followed by assessment for proliferation as per (A). *p < 0.05 compared with the same stimulus without PDE4 inhibitor.

106 PDE4 INHIBITORS BLOCK TLR7 AND TLR9 SIGNALING

Treatment of CLL cells with either R848 or CpG-B induced p65 nuclear translocation at 2 h, as judged by Western analysis of cytosolic and nuclear fractions. This translocation was markedly reduced by cotreatment with rolipram (Fig. 5A).

TLRs induce canonical NF-κB activation by inducing IKKβ-induced serine phosphorylation and subsequent proteosomal degradation of IκBa, resulting in the release of p65 and other NF-κB family members for translocation to the nucleus (46). Treatment of CLL cells with CpG-B induced IκBa phosphorylation and a reduction in total IκBa levels in a time-dependent manner, with little change in either total or phosphorylated IκBa 1 h after CpG-B treatment, but substantial phosphorylation and degradation apparent after 2 h. When measured at 2 h, rolipram modestly reduced CpG-B–induced IκBa phosphorylation in CLL cells and augmented corresponding total IκBa levels (Fig. 5B). To verify the reduction in p65 nuclear translocation following PDE4 inhibitor treatment by another technique, we carried out confocal immunofluorescence studies. p65 was detectable in the cytosol of resting or rolipram-treated CLL cells, but rarely present in the nucleus. Treatment with CpG-B induced nuclear translocation of p65, whereas rolipram cotreatment markedly reduced such translocation (Fig. 5C).
**PDE4 inhibitors reduce TLR7 and TLR9 ligand-induced IRF5 nuclear translocation, but do not alter IRAK1 degradation**

Ligands of MyD88-associated TLRs induce activation of IRAK4 and IRAK1, followed by TNFR-associated factor (TRAF)6-associated signaling that leads to nuclear translocation of the transcription factors NF-κB and IRF5 (47). Treatment of CLL cells with R848 or CpG-B for 2 hours induced translocation of IRF5 to the nucleus that was markedly reduced by cotreatment with rolipram (Fig. 6A). As previously reported for other TLR agonists, CpG-B treatment led to a decrease in IRAK1 levels 2–3 h after TLR ligand stimulation (48). Rolipram had no effect on basal levels of IRAK1, nor did it alter CpG-B–induced degradation of IRAK1 (Fig. 6B).

**PDE4 inhibitors block TLR7 and TLR9 ligand-induced TNF-α and IFN-α secretion by CLL cells, normal PBMC, and CD14+ monocytes, but do not block IL-10 or IL-6 secretion**

Serum levels of the proinflammatory cytokines TNF-α and IL-6 and the anti-inflammatory cytokine IL-10 are elevated in CLL patients and may play an important role in the biology of this disease (49, 50). R848 and CpG-B induced substantial levels of TNF-α secretion from leukemic cells, whereas Pam3CSK4 had little or no effect. All three TLR ligands induced IL-6 and IL-10 secretion. Cotreatment with rolipram markedly reduced TLR ligand-induced TNF-α secretion, but did not block IL-6 or IL-10 secretion (Fig. 7A–C).
TLR7 and TLR9 signaling is thought to play an important role in the pathogenesis of several autoimmune diseases, including SLE (51, 52). To assess whether the observed PDE4 inhibitor-induced blockade of TLR7 and TLR9 signaling observed in CLL also occurred in normal hematopoietic cells and therefore might be relevant to the treatment of such autoimmune illnesses, we next examined TLR7 and TLR9 signaling in PBMC from healthy donors. When PBMC are stimulated with TLR7 ligands such as RNA-containing immune complexes (ICs) or synthetic TLR9 ligands such as CpG-A, easily detectable IFN-\(\alpha\) production is

FIGURE 5. PDE4 inhibitors block TLR7 and TLR9 ligand-induced NF-\(\kappa\)B p65 nuclear translocation in CLL. (A) Leukemic cells from a CLL patient were incubated for 2 h with media alone, the TLR9 agonist CpG-B (5 \(\mu\)g/ml), or the TLR7 agonist R848 (3 \(\mu\)g/ml) either with rolipram or without rolipram (20 \(\mu\)M). Proteins extracted from the cytoplasmic and nuclear fractions of these cells were then Western blotted for NF-\(\kappa\)B p65 as well as the nuclear marker histone H2A. Blots are representative of eight CLL patients tested with CpG-B and three CLL patients tested with R848. (B) Leukemic cells from a CLL patient were incubated with vehicle alone or the TLR9 agonist CpG-B (5 \(\mu\)g/ml), rolipram (20 \(\mu\)M), or a combination of these two stimuli for 1, 2, or 3 h. Cell lysates were assessed by Western analysis for levels of total or phosphorylated IkB\(\alpha\). The relative loading of cell lysates for each experimental sample was established by also determining levels of lactate dehydrogenase on the same Western blot membrane. Blots are representative of five CLL patients tested. (C) The cytoplasmic or nuclear localization of NF-\(\kappa\)B p65 in CLL cells was determined after 2 h of incubation in media with vehicle alone, rolipram alone (20 \(\mu\)M), the TLR9 agonist CpG-B (5 \(\mu\)g/ml), or the combination of CpG-B and rolipram. NF-\(\kappa\)B p65 was localized by immunohistochemical analysis of permeabilized CLL cells using a confocal fluorescent microscope. In these images (original magnification \(\times100\)), p65 is labeled with Alexa Fluor 488 (green), and the nucleus is counterstained with TO-PRO-3 (blue). Images are representative of three patients tested. CT, control.

FIGURE 6. PDE4 inhibitors reduce TLR agonist-induced IRF5 nuclear translocation, but not IRAK1 degradation. (A) Leukemic cells from a CLL patient were incubated for 2 h with media alone, the TLR9 agonist CpG-B (5 \(\mu\)g/ml), or the TLR7 agonist R848 (3 \(\mu\)g/ml) in the absence or presence of rolipram (20 \(\mu\)M). Protein extracted from the cytoplasmic and nuclear fractions of the cells was then Western blotted for IRF5. The relative amounts of nuclear lysates loaded from these samples were assessed by blotting for the nuclear protein histone H2A. Blots are representative of five CLL patients tested. (B) Leukemic cells from CLL patients were incubated with vehicle alone or the TLR9 agonist CpG-B (5 \(\mu\)g/ml), rolipram (20 \(\mu\)M), or a combination of these two stimuli for 1, 2, or 3 h. Cell lysates were assessed by Western analysis for levels of IRAK1. The blot was then reprobed with lactate dehydrogenase or tubulin Abs as a control for the amount of lysate loaded. Blots are representative of three CLL patients tested.
FIGURE 7. TLR ligand-induced TNF-α and IFN-α secretion is inhibited by the PDE4 inhibitor rolipram in primary CLL cells and in PBMCs and CD14+ monocytes of normal donors, whereas IL-6 and IL-10 secretion is not inhibited. (A–C) Secretion of TNF-α (A), IL-10 (B), and IL-6 (C) by leukemic cells from CLL patients (n = 4) was assessed by ELISA following 24 h of culture in media/vehicle alone or varying concentrations of the TLR9 agonist CpG-B, the TLR7 agonist R848, or the TLR1/2 agonist Pam3CSK4 in the absence or presence of rolipram (20 μM). *p < 0.05. (D) Secretion of IFN-α by PBMCs from a normal donor was assessed by ELISA following 24 h of culture in media/vehicle alone or the plasmacytoid dendritic cell TLR9 agonist CpG-A (0.8 μg/ml) in the absence or presence of the indicated graded concentrations of rolipram. (E) Secretion of IFN-α by normal donor (n = 4) PBMCs was analyzed by ELISA following 24 h of culture in media/vehicle alone or the plasmacytoid dendritic cell TLR9 agonist CpG-A (0.8 μg/ml) with or without rolipram (20 μM). (F) IFN-α secretion of normal donor (n = 3) PBMCs was assessed by ELISA following 24 h of culture with media alone, 3% anti-Sm-RNP–containing SLE sera alone, Sm-RNP alone, or preformed anti–Sm-RNP/Sm-RNP ICs in the absence or presence of rolipram (20 μM). (G) Positively selected normal donor (n = 5) peripheral blood CD14+ monocytes were assessed for TNF-α secretion by ELISA following 24 h of culture with the TLR9 agonist CpG-B, TLR7/8 agonist R848, 3% anti–Sm-RNP–containing SLE sera alone, Sm-RNP alone, or preformed anti–Sm– (Figure legend continues)
limited to plasmacytid dendritic cells (pDC) as this is the only circulating cell that produces this cytokine at high levels in response to these stimuli (53, 54). When stimulated with CpG-A for 24 h, PBMC produced substantial levels of IFN-α that were reduced in a dose-dependent manner by cotreatment with the PDE4 inhibitor rolipram (Fig. 7D, 7E).

Although otherwise an effective TLR7/8 agonist, R848 does not effectively induce IFN-α in PBMC (37, 55). To instead examine TLR7-dependent responses of PBMC to a physiologic RNP IC stimulus, we incubated serum from a SLE patient containing anti-Sm/RNP Abs (37) with purified bovine Sm/RNP that contains endogenous mammalian RNA bound to the Sm/RNP protein in the native state (19). The resulting ICs were then added to PBMC in the presence or absence of rolipram. Whereas the Sm/RNP alone or the serum alone had no demonstrable effect, the Sm/RNP-containing ICs induced IFN-α production that was reduced by cotreatment with rolipram (Fig. 7F, n = 3, p = 0.08 for 1% serum).

Although circulating human monocytes do not express TLR9, they do express TLR7 and TLR8 and respond to synthetic TLR7/8 agonists. Circulating human monocytes from healthy donors were stimulated for 24 h with CpG-B, R848, Sm/RNP, anti-Sm/RNP serum, or Sm/RNP-containing ICs. As expected, CpG-B induced neither IL-6 nor TNF-α secretion in monocytes. However, both Sm/RNP-containing IC and R848 induced monocyte TNF-α secretion, and this was strongly inhibited by rolipram (Fig. 7G, 7I). In marked contrast, rolipram treatment did not inhibit R848-induced IL-6 production and actually enhanced monocyte IL-6 secretion, and this was strongly inhibited by rolipram (Fig. 7H, 7J).

**Discussion**

In this study, we have demonstrated that treatment with PDE4 inhibitors blocks signaling, proliferation, and cytokine production induced by TLR7 or TLR9 ligands in both CLL and normal human immune cells. Work in the field of autoimmunity has established the principle that B cells and dendritic cells undergo TLR7- and TLR9-mediated activation and proliferation in response to nucleoprotein complexes derived from endogenous apoptotic cells (56). We found that autologous apoptotic CLL cells induced proliferation of live CLL cells in a manner that could be inhibited by DNase, a TLR7/8/9 antagonist, or the PDE4 inhibitor rolipram. Such results are consistent with a growing body of literature suggesting that CLL cells may be derived from marginal zone B cells that normally clear apoptotic debris and bear BCRs specific for Ags expressed on apoptotic cells (1, 18, 19, 21, 22). Of interest, when CLL patient samples were assessed for IGHV mutational status and compared for their relative fold increase in proliferation in response to autologous apoptotic cells, seven of the top eight responders were IGHV unmutated samples, consistent with studies that have documented an enrichment in IGHV unmutated sequences among CLL samples whose BCRs bind to apoptotic cells (3). Although these differences were not statistically significant in this small sample group, a larger set of mutated and unmutated CLL samples will need to be examined to determine whether the observed trend is in fact a reproducible observation.

The effect of TLR signaling on CLL cell survival is controversial, with some authors reporting that TLR agonists induce apoptosis and others reporting no or even anti-apoptotic effects (9, 11, 13, 57, 58). Whereas PDE4 inhibitors themselves induced moderate apoptosis, we observed that the three TLR agonists induced little or no apoptosis in CLL samples at 72 h. Of some note, treatment with the TLR9 agonist CpG-B significantly reduced basal apoptosis in IGHV unmutated CLL cells, whereas no reduction in basal apoptosis was observed in IGHV mutated cases. This result suggests that TLR9 signaling may be of particular pathophysiologic importance in IGHV unmutated CLL patients. Furthermore, our observation that we are able to induce apoptosis in TLR9 agonist-treated IGHV unmutated cell samples by rolipram treatment is consistent with the hypothesis that PDE4 inhibitor-induced cAMP signaling results in abrogation of a TLR9 ligand-associated anti-apoptotic effect in leukemic cells from this poor prognostic subgroup of CLL patients.

Our results stand in some contrast to those of Fonte et al. (59), who, using a different apoptosis assay and a different time point, observed no difference in the effect of a TLR9 agonist on basal apoptosis in IGHV mutated or unmutated CLL cells. They did, however, find that the TLR9 agonist preferentially protected IGHV unmutated CLL cells from the induction of apoptosis by fludarabine relative to IGHV mutated samples. Although our preclinical data from this and prior studies suggest that PDE4 inhibitors are likely to induce only a modest degree of apoptosis in CLL cells when used alone, this class of drugs may nonetheless prove to be useful therapeutic agents for B cell malignancies when combined with other treatment regimens, particularly given their ability to augment glucocorticoid-induced apoptosis (31, 36, 60).

To more specifically establish whether PDE4 inhibitors might block signaling by the intracellular TLRs implicated in responses to apoptotic cell debris, we assessed CLL responses to synthetic TLR ligands. TLR1/2, TLR7, and TLR9 agonists induced upregulation of CD40 and CD54 expression and proliferation of CLL cells, and these responses were blocked by two structurally distinct PDE4 inhibitors, rolipram and roflumilast. PDE4 inhibitors block at least two signaling outcomes of TLR7 and TLR9 signal transduction: NF-κB p65 nuclear translocation and IRF5 nuclear translocation. Rolipram treatment reduced TLR7 or TLR9 agonist-induced 1kBα phosphorylation and augmented residual total 1kBα levels at 2 hours. When the earliest steps of TLR9 signal transduction were examined, we observed that CpG-B treatment consistently induced degradation of CLL cell IRAK1, a phenomenon previously linked to IRAK4-mediated phosphorylation of IRAK1 (48). This event was not altered by cotreatment with rolipram. These studies suggest that a PDE4 inhibitor-induced regulatory step occurs distal to IRAK1 activation and proximal to the branch point for NF-κB and IRF5 signaling. IRAK1 is known to bind to TRAF6, resulting in recruitment of TAB1/2 and TAB3 as well as TAK1. This complex regulates NF-κB activation by activating the IKK kinases. TRAF6 also binds IRF5. Thus, a logical focus for future research will be to assess whether PDE4 inhibitors alter TLR ligand-induced TRAF6-mediated signaling.

Rolipram markedly reduced CpG-B and R848-induced TNF-α secretion, but had no effect on TLR ligand-induced IL-10 or IL-6 secretion by CLL cells or purified monocytes. The anti-inflammatory cytokine IL-10 is known to have cAMP response elements in its promoter, and PDE4 inhibitor-induced PKA activation leads to AT1F1/CREB Ser63/133 phosphorylation that would
be expected to activate transcription in such cAMP response elements containing promoters. Thus, it is plausible that persistent IL-10 secretion in rolipram-treated CLL cells may be related to the summation of inhibition of TLR ligand-induced IL-10 transcription and concomitant ATF1/CREB-mediated activation of IL-10 transcription (35, 61–63). More striking, however, is the persistence of TLR ligand-induced IL-6 production in the face of PDE4 inhibitor treatment of CLL cells and purified monocytes. Our results are consistent with prior studies using the TLR4 ligand LPS, which documented that PDE inhibitors blocked TNF-α, but not IL-6 production in monocytes (64, 65). The Tec family cytoplasmic tyrosine kinase Btk has been reported as a critical mediator of LPS-induced TNF-α, but not IL-6 production in macrophages, whereas LPS-induced IL-6 production has been reported to be regulated by another Tec family kinase, Bmx (66, 67). The discrepant inhibition of TLR agonist-induced TNF-α and IL-6 signaling by PDE4 inhibitors may reflect differential effects of cAMP-mediated signaling on Tec family kinases.

IFN-α production by PBMC following TLR7 and TLR9 stimulation with Sm/RNP-containing ICs and by CpG-A, respectively, is the result of pDC activation (53, 54). A dendritic cell–derived IFN-α signature has been identified as a critical pathophysiologic event in patients with active SLE, and blockade of TLR7 and TLR9 function in circulating pDC from SLE patients has been shown to restore steroid sensitivity to such cells (52, 68). Abnormal synthesis of proinflammatory cytokines has also been observed in monocytes from SLE patients (69). NCS 613, a PDE4 inhibitor, has been reported to reduce disease activity in lupus-prone mice (70). We found that cotreatment with rolipram markedly reduced PBMC IFN-α production stimulated by TLR7 and TLR9 agonists. Rolipram also blocked both R848 and Sm/RNP-containing IC-induced synthesis of TNF-α in monocytes, but actually enhanced IC-induced synthesis of IL-6. The in vitro lack of activity of PDE4 inhibition on TLR ligand-induced IL-6 synthesis documented in this work will need to be examined carefully in assessing the potential clinical utility of PDE4 inhibitor therapy in autoimmune disease.

Overall, our results demonstrate that in both primary leukemic cells derived from CLL patients and in normal PBMC and purified monocytes, inhibition of PDE4 enzymes potently inhibits TLR7 and TLR9 ligand-induced signal transduction (NF-κB and IRF5 activation) as well as consequent alterations in cell surface Ag expression, proliferation, and inflammatory cytokine production. Although the varying stimuli used make it difficult to make a straightforward comparison, TLR7-mediated signaling appears to be at least as sensitive as TLR9 to rolipram-mediated inhibition. Rolipram blocks TLR signaling in both good prognosis IGHV mutated and poor prognosis IGHV unmutated CLL patients, although the basal pathophysiologic relevance of TLR9 signaling appears to be particularly important in the IGHV unmutated subset. Finally, our results demonstrate that CLL cells can be induced to proliferate by exposure to autologous apoptotic cells, and that this effect can be blocked by PDE4 inhibitors. These observations suggest that PDE4 inhibitors may be of use in the management of CLL patients and also provide further rationale for current efforts evaluating the use of PDE4 inhibitors in SLE and other TLR-driven autoimmune diseases (71, 72).

Acknowledgments

We thank David Seldin (Hematology/Oncology Section, Boston University School of Medicine), David Sherr (Department of Environmental Health, Boston University School of Public Health), Hanni Menn-Josephy and Kei Yasuda (Section of Nephrology, Boston University School of Medicine), and Mitch White (Hematology/Oncology Section, Boston University School of Medicine) for advice and assistance in this study.

Disclosures

The authors have no financial conflicts of interest.

References


